Judges rescues NH data in First Amendment rule

Share this article:
A New Hampshire law barring the commercial use of prescription data has been struck down on First Amendment grounds.

A federal judge agreed with the arguments of IMS Health and Verispan, which sued to block the law, dubbed the Prescription Privacy Protection Act. The law, which took effect last August, was aimed at keeping prescription data out of the hands of pharma manufacturers and crippling detailing efforts.

US District Judge Paul Barbadoro said: “Because the Prescription Information Law restricts constitutionally protected speech without directly serving the state’s substantial interests and because alternatives exist that would achieve the state’s interests as well or better without restricting speech, the law cannot be enforced to the extent that it purports to restrict the transfer or use of prescriber-identifiable data.”

The decision could forestall a gathering wave of state-level legislation aimed at stymieing drug reps by restricting companies’ access to data.

John Kamp, executive director of the Coalition for Healthcare Communication said the judge in the case “appropriately focused on the fact that the New Hampshire legislature wanted to reduce the sale of branded drugs.”

Kamp added the case was not only about New Hampshire but it was also about “New Hampshire wannabes” in other jurisdictions.

“The overturning of the New Hampshire law throws ice on top of any other state, including the federal government,” looking to enact look-alike bills, Kamp said.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.